Ocuphire Pharma Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025 VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025 Company will seek a strategic partner to continue development of
10/22/24 4:05:00 PM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2025 Preparatory Steps Towards Phase 2/3 with APX3330 in Diabetic Retinopathy are Ongoing Cash Position of $41.4 million Provides Runway Anticipated into mid-2025 FARMINGTON HILLS, Mich., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive e
8/13/24 8:00:00 AM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™," said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire. "We have been engaged in productive dialogue with the U.S. Food and Drug Administration (FDA) with respect to our submitted Special Protocol Assessmen
5/10/24 8:00:00 AM ET
$OCUP
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care

$OCUP
Press Releases

Fastest customizable press release news feed in the world

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (NASDAQ:OCUP) a clinical-stage ophthalmic biopharmaceutical company. The companies have combined under the name of Opus Genetics to create a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of inherited retinal diseases (IRDs). The combined company is trading on the Nasdaq under the ticker s
10/25/24 12:00:00 PM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care
Ocuphire Pharma Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025 VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025 Company will seek a strategic partner to continue development of
10/22/24 4:05:00 PM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced the publication of full results from two pivotal Phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and efficacy of RYZUMVI™ (Phentolamine Ophthalmic Solution 0.75%) for the treatment of pharmacologically-induced mydriasis in the peer-reviewed journal Ophthalmology. The results demonstrated that Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2
9/30/24 8:00:00 AM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care

$OCUP
Leadership Updates

Live Leadership Updates

Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today. George Magrath, M.D. M.B.A, M.S. CEO commented, "As the biology of Ref-
2/14/24 8:00:00 AM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of Joseph (Joe) K. Schachle, M.B.A., into the newly created role of Chief Operating Officer, effective today. "Joe is a highly accomplished pharmaceutical executive, and we are thrilled to welcome him to Ocuphire as Chief Operating Officer," said Dr. George Magrath, CEO of Ocuphire. "His appointment is part of a broader strategic initiative to expand our senior team as we plan for adv
11/27/23 8:00:00 AM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and member of the Board of Directors, effective today. Dr. Magrath succeeds Rick Rodgers, M.B.A., Interim Chief Executive Officer and President since April 2023. Mr. Rodgers will remain on the company's Board of Directors. "We are thrilled to have Dr. Magrath, a highly accomplished pharmaceutical executive with e
11/1/23 8:05:00 AM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care

FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

Products on NDA 217064

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217064

Original Approvals or Tentative Approvals

Chat with this insight

Recent Analyst Ratings for $OCUP

$OCUP Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Graves Adrienne L

Director Bennett Jean was granted 100,000 shares (SEC Form 4)

SEC Form 3 filed by new insider Yerxa Benjamin R

$OCUP Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Ocuphire Pharma Inc. (Amendment)

SEC Form SC 13G filed by Ocuphire Pharma Inc.

SEC Form SC 13G/A filed by Ocuphire Pharma Inc. (Amendment)

$OCUP Financials

Live finance-specific insights

Ocuphire Pharma Announces Acquisition of Opus Genetics

Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

$OCUP SEC Filings

SEC Form 10-Q filed by Ocuphire Pharma Inc.

Ocuphire Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$OCUP FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

$OCUP Press Releases

Fastest customizable press release news feed in the world

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

Ocuphire Pharma Announces Acquisition of Opus Genetics

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

$OCUP Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. initiated coverage on Ocuphire Pharma with a new price target

Alliance Global Partners initiated coverage on Ocuphire Pharma with a new price target

JonesTrading initiated coverage on Ocuphire Pharma with a new price target

$OCUP Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Jayagopal Ashwath bought $6,178 worth of shares (3,500 units at $1.76), increasing direct ownership by 5% to 78,500 units (SEC Form 4)

Magrath George bought $8,772 worth of shares (5,000 units at $1.75), increasing direct ownership by 1% to 430,000 units (SEC Form 4)

Schachle Joseph K bought $4,100 worth of shares (2,000 units at $2.05) (SEC Form 4)

$OCUP Market Insights

Live Market Insights

Ocuphire Pharma Participates In ARVO SIG Panel And ASRS 42nd Annual Scientific Meeting To Highlight APX3330 For Diabetic Retinopathy

Ocuphire Pharma Announces Upcoming Presentations On Lead Candidate APX3330 For Diabetic Retinopathy At Clinical Trials At The Summit On June 8 And Retinal Imaging Biomarkers & Endpoints Summit June 25-27

Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying

$OCUP Leadership Updates

Live Leadership Updates

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director

Recent Analyst Ratings for
$OCUP

$OCUP
Insider Trading

$OCUP
Large Ownership Changes

$OCUP
Financials

$OCUP
SEC Filings

$OCUP
FDA approvals

$OCUP
Press Releases

$OCUP
Analyst Ratings

$OCUP
Insider Purchases

$OCUP
Market Insights

$OCUP
Leadership Updates